Literature DB >> 8238799

The influence of IL-3, IL-5, and GM-CSF on normal human eosinophil and neutrophil C3b-induced degranulation.

M Carlson1, C Peterson, P Venge.   

Abstract

The priming effect of interleukin-3 (IL-3), interleukin-5 (IL-5), and granulocyte/macrophage-colony stimulating factor (GM-CSF) on eosinophil and neutrophil degranulation was studied. Granulocytes were obtained from normal donors, and degranulation was induced by incubation with serum-opsonized Sephadex particles. The released amounts of eosinophil cationic protein (ECP), eosinophil protein X (EPX), myeloperoxidase (MPO), and lactoferrin (LF) were measured by radioimmunoassay (RIA). The effect of IL-5 was dose- and time-dependent, with a maximal enhancement of ECP and EPX release of 71% (P < 0.03) and 66% (P < 0.03), respectively. Neutrophil degranulation, however, was unaffected. IL-3 was marginally effective, whereas GM-CSF seemed to act as a secretagogue for both eosinophil and neutrophil degranulation. We conclude that IL-5 selectively primes eosinophil degranulation, whereas IL-3 and GM-CSF seem to act as secretagogues for eosinophils and neutrophils. The results indicate that IL-5 may be involved in the priming of eosinophils as observed in patients with asthma and hypereosinophilic syndrome (HES).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8238799

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  15 in total

1.  IL-5 induces suspended eosinophils to undergo unique global reorganization associated with priming.

Authors:  Shih-Tsung Han; Deane F Mosher
Journal:  Am J Respir Cell Mol Biol       Date:  2014-03       Impact factor: 6.914

2.  Cytokines induce selective granulocyte chemotactic responses.

Authors:  D B Bittleman; R A Erger; T B Casale
Journal:  Inflamm Res       Date:  1996-02       Impact factor: 4.575

Review 3.  Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer.

Authors:  Zhaleh J Amini-Vaughan; Margarita Martinez-Moczygemba; David P Huston
Journal:  Curr Allergy Asthma Rep       Date:  2012-10       Impact factor: 4.806

4.  Priming effect of platelet activating factor on leukotriene C4 from stimulated eosinophils of asthmatic patients.

Authors:  K Shindo; K Koide; Y Hirai; M Sumitomo; M Fukumura
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

5.  AVE 0991, a non-peptide mimic of angiotensin-(1-7) effects, attenuates pulmonary remodelling in a model of chronic asthma.

Authors:  M G Rodrigues-Machado; G S Magalhães; J A Cardoso; L M Kangussu; A Murari; M V Caliari; M L Oliveira; D C Cara; M L M Noviello; F D Marques; J M Pereira; R Q Lautner; R A S Santos; M J Campagnole-Santos
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

6.  Ouabain attenuates ovalbumin-induced airway inflammation.

Authors:  José Guilherme F M Galvão; Luiz Henrique Agra Cavalcante-Silva; Deyse Cristina M Carvalho; Laércia Karla D P Ferreira; Talissa Mozzini Monteiro; Adriano Francisco Alves; Larissa Adilis M P Ferreira; Francisco Allysson A F Gadelha; Marcia Regina Piuvezam; Sandra Rodrigues-Mascarenhas
Journal:  Inflamm Res       Date:  2017-09-13       Impact factor: 4.575

7.  Innate antifungal immunity of human eosinophils mediated by a beta 2 integrin, CD11b.

Authors:  Juhan Yoon; Jens U Ponikau; Christopher B Lawrence; Hirohito Kita
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

8.  The Role of the T lymphocytes and Remodeling in Asthma.

Authors:  Kawa Amin
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

9.  Patients with allergic rhinitis and allergic asthma share the same pattern of eosinophil and neutrophil degranulation after allergen challenge.

Authors:  Mary Kämpe; Ingrid Stolt; Maria Lampinen; Christer Janson; Gunnemar Stålenheim; Marie Carlson
Journal:  Clin Mol Allergy       Date:  2011-01-21

10.  Galectin-Receptor Interactions Regulates Cardiac Pathology Caused by Trichinella spiralis Infection.

Authors:  Jinghai Yan; Shiguang Huang; Fangli Lu
Journal:  Front Immunol       Date:  2021-05-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.